Physician profile
Cherrell M Shells
NPI 1033410451
$2,721.20
in general payments reported to CMS, 2019-2025
28 companies · $1,286 in 2025
The $1,286 reported for 2025 was more than what 89% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.41 · 2022: $133 · 2023: $372 · 2024: $888 · 2025: $1,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $456.98 | 2024-2025 | Fanapt |
| Abbvie INC. | $422.80 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $230.65 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $219.69 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $175.24 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $147.83 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $131.65 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $107.36 | 2022-2025 | Eliquis, Cobenfy |
| Azurity Pharmaceuticals, INC. | $104.66 | 2024-2025 | Horizant |
| Astrazeneca Pharmaceuticals Lp | $96.60 | 2024-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $65.27 | 2021-2024 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $55.78 | 2024-2025 | |
| Glaxosmithkline, LLC. | $55.39 | 2023-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $55.29 | 2023-2024 | Auvelity |
| Amgen INC. | $50.80 | 2022-2024 | Otezla, Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $41.47 | 2023-2024 | Veklury |
| Lundbeck LLC | $35.43 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $33.62 | 2022 | |
| Sumitomo Pharma America, INC. | $33.12 | 2023-2024 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $31.65 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.95 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $26.00 | 2025 | Uzedy |
| Abbott Laboratories | $24.31 | 2024 | Freestyle Libre 3 |
| Aimmune Therapeutics, INC. | $23.82 | 2025 | Zenpep |
| Neurocrine Biosciences, INC. | $22.59 | 2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $17.01 | 2024 | Trintellix |
| Smith+Nephew, INC. | $15.28 | 2025 | Collagenase Santyl |
| Inari Medical, INC. | $13.96 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherrell Shells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.